Osivax, a developer of broad-spectrum vaccines, has appointed Nicola Groth to its executive committee as chief medical officer. The appointment comes as the company advances its lead candidate influenza vaccine into Phase 2. Dr Groth is experienced in managing late-stage clinical trials and building registration packages for influenza vaccines. Prior to joining Osivax, she headed global safety evaluation and risk management at GlaxoSmithKline Vaccines and has also held strategic positions in vaccine development, epidemiology and medical affairs at Novartis Vaccines. Dr Groth is a doctor of medicine and holds a PhD in hygiene and preventive medicine from the University of Siena, Italy.
Osivax announced the appointment on 25 January 2024.
Copyright 2024 Evernow Publishing Ltd